BioToxTech Co

BioToxTech Co LT Debt/Equity

The Long-Term Debt to Equity Ratio of BioToxTech Co (086040.KQ) as of Nov 12, 2026 is 0.28. In the previous year, Long-Term Debt to Equity Ratio was 0.41 — a change of -31.18% (lower).

LT Debt/Equity

0.28

YoY

-31.18%

Last updated:

Long-Term Debt to Equity Ratio of BioToxTech Co is 2025 0.28 . Long-Term Debt to Equity Ratio of BioToxTech Co was 2024 0.41 . It decreases by -31.18% lower compared to the previous year.

The BioToxTech Co LT Debt/Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

LT Debt/Equity
Date
LT Debt/Equity
Jan 1, 2018
0.05 KRW
Jan 1, 2019
0.20 KRW
Jan 1, 2020
0.09 KRW
Jan 1, 2021
0.05 KRW
Jan 1, 2022
0.46 KRW
Jan 1, 2023
0.39 KRW
Jan 1, 2024
0.41 KRW
Jan 1, 2025
0.28 KRW
The BioToxTech Co LT Debt/Equity history
YEARLT Debt/EquityYoY
0.28-31.18%
0.41+4.25%
0.39-14.22%
0.46+833.49%
0.05-44.14%
0.09-55.61%
0.20+309.77%
0.05+112.69%
0.02—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BioToxTech Co Stock analysis

What does BioToxTech Co do? Biotoxtech Co., Ltd. generates revenue through non-clinical drug trials, offering safety evaluation research, efficacy evaluation research, and analysis research services. Safety evaluation includes general toxicity, local toxicity, reproductive and development, genotoxicity, immunotoxicity, carcinogenicity, safety pharmacology, ecotoxicology, histopathology, and hematology tests. Efficacy evaluation covers medical supplies, health supplements, and cosmetics. Analysis research provides pharmacokinetics (PK) and toxicokinetics (TK) tests, validation, and bio analysis services. The company serves clients requiring preclinical testing for pharmaceuticals, health products, and cosmetics. The firm expanded its operations by acquiring a 60% stake in a newly established subsidiary on March 13, 2013. This strategic move enhances its capacity to deliver comprehensive research services. Clients include pharmaceutical companies, health supplement manufacturers, and cosmetic brands seeking regulatory compliance and product safety validation before market entry. Biotoxtech's service portfolio targets the pharmaceutical, health supplement, and cosmetic industries. Its safety and efficacy testing ensures products meet regulatory standards, supporting clients in developing safe and effective formulations. The company's analysis research further aids in optimizing drug delivery and performance through PK and TK assessments. BioToxTech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BioToxTech Co stock

Long-Term Debt to Equity Ratio of BioToxTech Co is 0.28 in 2025.

Long-Term Debt to Equity Ratio of BioToxTech Co changed from 0.41 to 0.28, representing a -31.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio BioToxTech Co since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's BioToxTech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BioToxTech Co

All Key Metrics — BioToxTech Co